Memantine Grindeks

Memantine, the active ingredient in Memantine Grindeks, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is indicated for the treatment of Alzheimer’s disease in adults. GNH USA supplies Memantine Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine is used in the management of neurodegenerative conditions that involve glutamate‑mediated excitotoxicity. Alzheimer's disease: improves cognition and functional abilities in mild‑to‑moderate stages.

Common Side Effects: - Dizziness: transient light‑headedness reported by some patients. - Headache: mild to moderate intensity, often resolves with continued therapy. - Constipation: reduced bowel movements, manageable with diet. - Fatigue: feeling of tiredness, usually improves over time. - Hypertension: modest increase in blood pressure in a minority. - Confusion: occasional episodes of mental clouding. Serious or Rare Side Effects: - Seizures: rare but may occur, especially in patients with a seizure history. - Cardiac arrhythmia: uncommon irregular heart rhythms. - Hepatic injury: elevated liver enzymes reported in isolated cases. - Stevens‑Johnson syndrome: severe skin reaction, extremely rare. - Psychosis: emergence of hallucinations or delusions in susceptible individuals. - Suicidal thoughts: rare emergence of suicidal ideation.

Memantine should be used with caution in specific clinical situations. Renal impairment: dose adjustment may be required in patients with reduced kidney function. Hepatic impairment: monitor liver function tests during therapy. History of seizures: assess risk and consider alternative therapy. Concurrent NMDA antagonists: avoid combining with other agents that block NMDA receptors. Pregnancy and lactation: insufficient data; use only if potential benefit justifies potential risk. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with several medicines that affect the central nervous system. Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neuropsychiatric effects. - Ketamine: combined NMDA blockade can lead to excessive sedation or cognitive impairment. Moderate Interactions (Monitor Closely): - Anticholinergics: may diminish cognitive benefits of memantine. - Diuretics: can potentiate hypotensive effects. - CNS depressants (e.g., benzodiazepines): increased risk of drowsiness and coordination problems.